Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinopharm Leads $20 Million Investment in Singapore's Novena; Plans Joint $150 Million Healthcare Fund

publication date: Jun 25, 2019

Novena Global Lifecare, a Singapore company with 250 aesthetic clinics and sales outlets in southeast Asia, will receive an investment of up to $20 million from Sinopharm Capital and Cedarlake Capital. Founded in 2010, Novena is one of the largest medical healthcare and aesthetic groups in the region. In addition, the three companies plan to raise as much as $150 million for a new Sino-Singapore Healthcare Fund. The fund will invest in southeast Asian medical services, biomedical projects, mature drugs and precision medical drugs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital